Alexander Polinsky, PHD

Alexander Polinsky received his Ph.D. in Physical Chemistry from Moscow University, Russia, and was on the faculty at Moscow University studying synthetic vaccines. After moving to the U.S. in 1988, he spent 2.5 years at UCSD developing new methods for computer-aided drug design. In 1991, Dr. Polinsky co-founded the Alanex Corporation in San Diego and developed novel combinatorial chemistry technology; he served as Alanex’ CSO until it was acquired by Agouron in 1997.
After the acquisition by Pfizer in 2000, Dr. Polinsky became Vice President, Head of Discovery Technologies, at the Pfizer La Jolla Labs. In 2006, he moved to Global Research Technology department where he led the development of Pfizer External Research Network concept. In 2007, Dr. Polinsky established The Pfizer Incubator (TPI) and became its CEO.
In 2011, Dr. Polinsky co-founded and became a CEO of OncoTartis, Inc. Over the years, Dr. Polinsky has served on the Boards of three private and two public companies.